- Patterson Companies Inc PDCO reports Q4 FY22 sales of $1.64 billion, +4.9% Y/Y, beating the consensus of $1.59 billion.
- Dental segment sales reached $636.4 million. Internal sales increased 3.4% Y/Y, including a 0.8% decline in consumables due to the expected moderation of infection control products compared to the pandemic-related performance last year.
- "Patterson delivered an excellent fourth quarter, culminating a year in which we delivered both top and bottom-line growth that exceeded our expectations," said Mark Walchirk, President and CEO.
- Animal Health segment sales reached $1 billion. Internal sales growth of 7.6% was driven by continued strong performance in companion and production animals.
- The gross margin improved to 21.2% from 19.5% a year earlier.
- Patterson reported an adjusted EPS of $0.71, surpassing the consensus of $0.55, almost double from $0.38 posted a year ago.
- The company returned $136.1 million to shareholders in fiscal 2022 through dividends and share repurchases.
- Guidance: Patterson Companies expects FY23 adjusted EPS of $2.25 - $2.35, versus the consensus of $2.24.
- Price Action: PDCO shares are up 9.98% at $30.75 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in